US Patent Issued to Purdue Pharma on July 29 for "Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia" (Swiss, German Inventors)

ALEXANDRIA, Va., July 30 -- United States Patent no. 12,370,178, issued on July 29, was assigned to Purdue Pharma LP (Stamford, Conn.).

"Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia" was invented by Thomas Jorg Mehrling (Riehen, Switzerland) and Marco Herling (Cologne, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof."

The patent was filed on Jan. 25, 2024, under Application No. 18/422,118.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/np...